Ciérvide, R.; Montero, Á.; García-Rico, E.; García-Aranda, M.; Herrero, M.; Skaarup, J.; Benassi, L.; Barrera, M.J.; Vega, E.; Rojas, B.;
et al. Primary Chemoradiotherapy Treatment (PCRT) for HER2+ and Triple Negative Breast Cancer Patients: A Feasible Combination. Cancers 2022, 14, 4531.
https://doi.org/10.3390/cancers14184531
AMA Style
Ciérvide R, Montero Á, García-Rico E, García-Aranda M, Herrero M, Skaarup J, Benassi L, Barrera MJ, Vega E, Rojas B,
et al. Primary Chemoradiotherapy Treatment (PCRT) for HER2+ and Triple Negative Breast Cancer Patients: A Feasible Combination. Cancers. 2022; 14(18):4531.
https://doi.org/10.3390/cancers14184531
Chicago/Turabian Style
Ciérvide, Raquel, Ángel Montero, Eduardo García-Rico, Mariola García-Aranda, Mercedes Herrero, Jessica Skaarup, Leticia Benassi, Maria José Barrera, Estela Vega, Beatriz Rojas,
and et al. 2022. "Primary Chemoradiotherapy Treatment (PCRT) for HER2+ and Triple Negative Breast Cancer Patients: A Feasible Combination" Cancers 14, no. 18: 4531.
https://doi.org/10.3390/cancers14184531
APA Style
Ciérvide, R., Montero, Á., García-Rico, E., García-Aranda, M., Herrero, M., Skaarup, J., Benassi, L., Barrera, M. J., Vega, E., Rojas, B., Bratos, R., Luna, A., Parras, M., López, M., Delgado, A., Quevedo, P., Castilla, S., Feyjoo, M., Higueras, A.,
... Rubio, C.
(2022). Primary Chemoradiotherapy Treatment (PCRT) for HER2+ and Triple Negative Breast Cancer Patients: A Feasible Combination. Cancers, 14(18), 4531.
https://doi.org/10.3390/cancers14184531